Skip to main content
. 2011 Jul 22;5(6):e544–e551. doi: 10.1111/j.1750-2659.2011.00272.x

Table 2.

 Comparison of characteristics of ward versus pediatric intensive care unit (PICU) patients

Ward patients PICU patients P*
n = 466 n = 51
Number (%) Number (%)
Male sex 283 (60·7) 29 (56·9) 0·59
Mean age (years) 4·7 ± 3·9 4·4 ± 3·7 0·6
Clinical signs and symptoms
Fever 452 (97·2) 48 (94·1) 0·23
Upper respiratory tract manifestations
 Cough 413 (88·8) 42 (82·4%) 0·17
 Rhinorrhea 335 (72) 34 (69·4) 0·69
 Odynophagia 57 (12·4) 5 (10·9) 0·76
Breathing difficulty 219 (47·2) 39 (78) <0·001
General symptoms
 Headache 53 (11·6) 1 (2·2) 0·07
 Myalgias 42 (9·2) 1 (2·2) 0·16
 Irritability/malaise 178 (38·4) 18 (38·3) 0·98
Gastrointestinal symptoms
 Vomiting 136 (29·4) 8 (16·3) 0·05
 Diarrhea 67 (14·4) 2 (4·1) 0·04
Mean time from symptom onset to hospital admission (days) 4·1 ± 10·7 2·5 ± 1·7 0·3
Abnormal chest radiograph 67% 88% <0·01
Blood test results
 White blood cell count (cells/mm3) 9994 ± 5988 9430 ± 6537 0·57
 Lymphocytes (cells/mm3) 2702 ± 2868 1590 ± 1298 <0·001
 Neutrophils (cells/mm3) 6026 ± 4970 6804 ± 5981 0·41
 C‐reactive protein (mg/l) 34·3 ± 52·7  45 ± 68·6 0·31
Treatment
 Oseltamivir 346 (74·9) 43 (86) 0·08
 Antibiotics 223 (49·2) 41 (80·4) <0·0001
 Bronchodilators 215 (46·6) 29 (58) 0·12
 Oxygen supplementation 173 (37·7) 48 (94·1) <0·0001
 Intravenous fluid therapy 161 (35·2) 43 (87·8) <0·0001
Underlying health conditions
 Any 113 (24·2) 29 (56·9) <0·001
 Moderate or severe persistent asthma 30 (6·4) 5 (9·8) 0·36
 Other chronic lung disorders (e.g. cystic fibrosis, bronchopulmonary dysplasia, obliterant bronchiolitis) 15 (3·2) 4 (7·8) 0·11
 Immunosuppression (because of underlying disease and/or therapy) or immunodeficiency 28 (6) 8 (15·7) <0·01
 Neurological or neuromuscular disorders 22 (4·7) 8 (15·7) <0·01
 Heart disease 23 (4·9) 4 (7·8) 0·33
Complications
 Any 85 (18·2) 47 (92·2) <0·0001
 Confirmed or suspected bacterial pneumonia 52 (11·1) 20 (39·2) <0·0001

Statistically significant differences are shown in bold.